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Question
Macrophage activation syndrome is a severe complication
of autoimmune and autoinflammatory disease. MAS is
most strongly associated with systemic juvenile idiopathic
arthritis (sJIA) but can also be seen in Kawasaki disease,
SLE or IBD. Clinically, MAS is strikingly similar to hemo-
phagocytic lymphohistiocytosis (HLH) and the initial dif-
ferentiation between sJIA-associated MAS and hereditary
HLH or acquired HLH is very difficult. Due to recent
advances in the description of HLH-related gene defects,
most patients with hereditary HLH can be identified
through genetic or functional analysis (intracellular per-
forin, SLAM-associated protein analysis, x-linked inhibitor
of apoptosis, CD107 degranulation assay). Unfortunately
these investigations are not always easily available. Since
viral infections such as EBV and CMV can trigger both
hereditary and acquired forms of HLH, the presence of a
viral trigger in a patient with HLH does not necessarily
allow classification of the disease as acquired HLH.
S100A12 is an endogenous TLR4 ligand that induces
monocyte activation, thereby acting as an amplifier of
innate immunity during early inflammation. S100A12 is
highly overexpressed in sJIA, and the assessment of
S100A12 serum levels helps distinguish sJIA from other
febrile illnesses. The main goal of this study was to
determine whether S100A12 might help distinguish
sJIA-associated MAS from HLH.
Methods
S100A12 serum levels were assessed in 177 samples
obtained from 114 unique patients using the in-house
ELISA kit. Of 177 samples, 152 samples were also avail-
able for a multiplex immunoassay including 53 cytokines
and chemokines. Serum samples were obtained from 9
healthy controls, sJIA patients without MAS (17 active/
19 remission), sJIA patients with MAS (33 active/ 33
remission), acquired HLH (22 active/ 20 remission) and
33 patients with hereditary HLH at disease onset. Addi-
tional data obtained at the time of serum collection
included clinical features, conventional laboratory mar-
kers (CRP, ESR, differential blood count, fibrinogen, fer-
ritin, triglycerides) and when available, NK cell function
test results and sCD25 levels.
Results
Patients with hereditary and acquired HLH could be
differentiated by S100A12 serum levels from patients
with sJIA-associated MAS. S100A12 levels >1400 ng/ml
were seen only in patients with active sJIA (with MAS
(mean±SD 5470±3042 ng/m)l or without MAS
(4150±3251 ng/ml), but not in patients with acquired
(451±351 ng/ml) or hereditary HLH (216±170 ng/ml).
Healthy controls were in the range of 85±44 ng/ml.
Although S100A12 levels correlated closely with dis-
ease activity in sJIA patients as determined by JIA core
set criteria, there was no significant difference between
sJIA patients with or without MAS.
Conclusions
S100A12 serum levels are useful to differentiate between
sJIA-associated MAS and inherited or acquired HLH.
The combination with conventional laboratory markers,
serum cytokine profiles and clinical characteristics might
allow creating a diagnostic panel for the differentiation of
MAS vs. HLH. Since at the onset of disease sJIA MAS
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and acquired HLH are difficult to discriminate this might
be a helpful diagnostic tool.
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